Immunology is the branch of biomedical sciences concerned with the study of the physiopathology of the immune system. The study of immunology seeks to solve problems posed by complex pathologies of particular importance to public health. Through methodological development, immunology has become an essential tool in biotechnology, in the design of drugs and diagnostic instruments, and in a multitude of therapeutic applications. Immunology is a key field in biomedical research around the world. This is directly related to the extraordinary advances in healthcare produced in the field of immunology over the past fifty years: vaccines, transplants, antibodies, anticancer therapy, cell differentiation factors, and anti-inflammatory drug therapy. The master’s degree Immunology provides knowledge and skills that offer students a wide range of opportunities in many areas, such as research and education, biotechnology, medicine and veterinary science. A comprehensive understanding of the immune system also equips students to evaluate pathological processes that directly involve the immune system or are associated with other physiological systems.
The Master in Advanced Immunology, is shared between the Universitat de Barcelona (current coordinator center) and the Universitat Autònoma de Barcelona.
In accordance with the provisions of Article 25.7 of Royal Decree 1393/2007, the proposal for the Master in Immunology was POSITIVELY VERIFIED (the verification was made by ANECA).
The Master in Immunology is part of the formative stage of the following doctoral programs:
- PhD Program in Biomedicine (Quality Mention MEE2011-0382) at the Universitat de Barcelona .
- PhD Program in Immunology (Quality Mention MCD2007-00235) from the Universitat Autònoma de Barcelona and Universitat de Barcelona .
The Master in Advanced Immunology (Originally called as Immunology) was approved by the Government of Catalonia in order UNI/263/2006 of 18/04/2006, published in the Catalan Government Gazette DOGC núm 4623 de 28/04/2006.
The Master in Advanced Immunology,was POSITIVELY VERIFIED by the Catalan University Quality Assurance Agency (AQU Catalunya). The official status of this master is reflected in the BOE nº 274 (pag 91413) de 15 de noviembre de 2013 .
The Syllabus of the Master in Advanced Immunology has been officially published in the Spanish Official Gazette nº 263 (pag. 88600) on 30 October 2014.
Master in Advanced Immunology has passed, during February 2016, the ACCREDITATION
process carried out by AQU . The ACCREDITATION process has assessed the
following dimensions: Quality of the training program, Relevance of public
information, Efficiency of the internal quality assurance system, Teacher
adaptation to the training program, Efficiency of learning support systems and
Quality of the results of the training program. The set of assessments made has
supposed to value the Master in Advanced Immunology UB-UAB with the highest
rating of EXCELLENT (12/01/2016). This RESOLUTION is also included in the Register of Universities, Centers and Titles (RUCT) of the Ministry of Education, Culture and Sport.
August 31, 2015, the Education, Audiovisual and
Culture Executive European Agency (EACEA) approved the Erasmus Mundus Plus JMD program
in Vaccinology to be launched in 2016-2017 course. The consortium, called LIVE
(Leading International Vaccinology Education) , is composed by five
universities: University Claude Bernard Lyon 1 (coordinator), Autonomous
University of Barcelona, University of Barcelona, University of Antwerp and
University Jean Monnet Saint-Etienne. This consortium has combined three
official masters, such as the Master of Advanced Immunology at the University
of Barcelona and the Autonomous University of Barcelona, the Master in
Infectious and Tropical Diseases at the University of Antwerp and the Master in
Genetics & Cell Biology-Fundamental Infectiology from the Universities of
Lyon and Saint-Etienne, to give rise to Erasmus Master Plus in Vaccinology
(LIVE). The journal Vaccine dedicates an editorial to the posgrade. We are delighted to announce that the Master LIVE was selected again in 2018, within the 42 Joint Erasmus + Mundus Masters (LIVE + EMJMD) to maintain the EMJMD label (92/100 points, threshold at 79/100). Consequently, the Master LIVE receives support from the Erasmus + program of the European Union with a grant of € 3,934,000 awarded to the LIVE consortium, for the period 2018-2024. This means starting the 2019-20 academic year the second stage with 4 biannual promotions.
LIVE combines the complementary elements of the
programs that already exist in the Masters from the each participating
university, resulting in a training program of 120 ECTS, multidisciplinary,
international, and with a deep commitment to the training of professionals with
3 very specific objectives such as: Learning Immunology and Infectiology to
become an expert in Vaccinology; Integrate academic and industrial network
internationally, and to be Participants of public policies on health and
education related to knowledge, development and application of vaccines.
In addition there are seven higher education
institutions associated: Ecole Normale Superieure de Lyon, University of
Firenze, Free University of Brussels, University of Arkansas Medical School,
University of British Columbia, Fudan University Shanghai Medical College,
University of Sao Paulo, and has more 50 centers and companies involved in the
research, development and manufacture of vaccines where students can develop